Integration of acquired immunity into microbial risk assessment for illness incidence is of no doubt essential for the study of susceptibility to illness. In this study, a probabilistic model was set up as dose response for infection and a mathematical derivation was carried out by integrating immunity to obtain probability of illness models. Temporary acquire immunity from epidemiology studies which includes six different Norovirus transmission scenarios such as symptomatic individuals infectious, pre-and post-symptomatic infectiousness (low and high), innate genetic resistance, genogroup 2 type 4 and those with no immune boosting by asymptomatic infection were evaluated. Simulated results on illness inflation factor as a function of dose and exposure indicated that high frequency exposures had immense immunity build up even at high dose levels; hence minimized the probability of illness. Using Norovirus transmission dynamics data, results showed, and immunity included models had a reduction of 2e6 logs of magnitude difference in disease burden for both population and individual probable illness incidence. Additionally, the magnitude order of illness for each dose response remained largely the same for all transmission scenarios; symptomatic infectiousness and no immune boosting after asymptomatic infectiousness also remained the same throughout. With integration of epidemiological data on acquired immunity into the risk assessment, more realistic results were achieved signifying an overestimation of probable risk of illness when epidemiological immunity data are not included. This finding supported the call for rigorous
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Introduction
The adoption of quantitative approach in modeling epidemiological risk over the years has gained interest in the field of disease modeling and epidemiology. This approach has led to the use of adopting techniques in characterizing uncertainty of input parameters with cumulative density functions, probability density functions and probability mass functions.
Mathematical epidemiology of diseases with compartmental models have covered almost all forms of diseases emphasizing the different transmission approaches with intervention inclusion models. Yet, only a few studies have been concentrating on using the same approach for the pathogen of interest causing such diseases. The transition of infection to illness for pathogens has received less attention in quantitative risk modeling (Havelaar & Swart, 2014) . This is as a result of lack of integration of epidemiological studies approach in quantitative risk assessment, such as a quantitative model of a susceptible individual suffering from pathogenic attack, transiting from partial recovery to become susceptible again (Swart, Tomasi, Kretzschmar, Havelaar, & Diekmann, 2012) .
In the light of the above, this study attempts to apply the integration of mathematical epidemiological method into quantitative risk assessment for modeling probability of illness by incorporating acquired immune function to predict the expected probability of illness for exposure to norovirus, a major gastrointestinal pathogenic virus.
Literature and review of mathematical probability of infection
Developing a mathematical dose response relationship is the same as establishing the relations between level of pathogen, exposure and the measure of likelihood occurrence of adverse effects (Haas, Rose, & Gerba, 2014, pp. 267e321 ). Furumoto and Mickey (1967) in estimating the consequences of exposure to different level of pathogens noted that, the process of infection is considered to be two sequential sub processes, namely; i. One or more organism(s) or virus particles ingested is (are) capable of causing diseases ii. An ingested organism/virus particle can become inactivated to multiply to cause infection/disease by host susceptible responses, and only a fraction of the ingested organisms reaches a site where infection can begin by breaking all barriers within the body immune system.
Hence, ingestion precisely j organism from exposure with a mean dose d is expressed as
P1ðjjdÞ
( 1) Therefore, probability of k surviving pathogen particles to initiate an infection process is also express as P2ðkjjÞ
Assuming independency for the two processes, the probability of k organisms surviving to initiate infection by breaking all defense mechanism within the body is given by the independent event
The least number of organisms (kmin) surviving to initiate an infection leads to a probability of infection
Where (kmin) is not the minimal infection dose or threshold needed to be reached to cause an infection.
Derivation of exponential dose response model
Characterizing the distribution of organisms between each dose as random and assuming independency for each ingested organism has an identical survival probability 1 r and kmin ¼ 1 (thus for a single hit assumption). Hence from Poisson distribution of organisms with the use of equation (1) 
Hence, substituting equations (5) and (6) into equation (4) and accounting for infectivity of the virus 'r' leads to the expression below
ðj À kÞ!
But
With the earlier single hit assumption (thus one organism survived is capable to cause an infection) kmin ¼ 1 yields
Derivation of the Beta-Poisson dose response model
Replacing equation (6) with a mixture distribution with respect to the parameter r to account for variability in the infectivity interaction probability yields equation (10) P2ðkjjÞ ¼
Equation (6) through various mathematical formulation yields equation (10), therefore, a mixture distribution application on equation (9) for a variation in the dose to dose in the poison distribution yields
Let the variation on dose to dose assume the beta distribution and for the purposes of a great deal of flexibility due to its suitable applications (Haas et al., 2014, pp. 267e321) , hence incorporating into equation (12) 
The integral can best be expressed as confluent hyper-geometric function of the first kind written as a series expansion
Therefore, the exact solution of the beta ePoisson model can be written as Teunis et al. (2008) noted that, the ingestion of a virion is based on whether it is aggregated or disaggregated, as virion particles may or may not be aggregated depending on the circumstances of the environment. Hence the confluent hypergeometric function yields: Furumoto and Mickey (1967) derived the following expression approximation to equation (14) based on the certain valid parameter values, thus when b 1 and w < b the simple relation holds. Furumoto and Mickey (1967) noted, any changes in b cause the Beta Poisson dose response relation to be shifted along the dose axis without changing shape. However, the hyper-geometric relation cannot be scaled due to its non-scalability of the beta distribution for r (Teunis, 2005) .
Beta Poisson to fractional Poisson model
Accounts from Teunis et al. (2008) noted, in applying equation (16) for quantification of probability of illness, human ingestion of virus particles found to share a common probability ðrÞ independently capable of initiating infection in subjects, though it is admitted some subjects may have very small values of r near zero and vice versa. Therefore, the aggregated norovirus infection probability is a beta function parameters described as Pinfðd; w; bÞ
Where w , b are shape parameters of beta distribution, a is the particle size, hence mean aggregate size mðaÞ is of the form
The result in probability of subjects receiving exactly zero aggregate is e Àd = mðaÞ and those with one or more aggregate is 1 À e Àd = mðaÞ .
Integration of temporary immunity in dose response model
Messner, Berger, and Nappier (2014) noted that, variation in probability of infection across a susceptible population is described with a mixture distribution by the use of beta parameters, hence describing individual probability of infection with Bernoulli distribution as a mixture model.
r $ BernoulliðpÞ
Therefore, individual probability of infection is exactly 1 with probability p and exactly 0 with probability 1 À p, and cannot assume any value within the interval 0-1with a parameter derivation of j, this incorporation led to probability of infection described by as:
Exposure scenarios
Given that, illness is independent of its previous events, then the probability of illness can be described with a Bernoulli distribution with fixed exposure (E) for a period of time in a known population of size N (Messner et al., 2014) . Therefore, the total sum of illness could be derived as a "Naïve Model" (Hass et al., 1999) described as Pill ¼ Pilljinf Pinf , hence the derivation is given as
For cases of independency of infection to exposure, Pilljinf ¼ 4, the conditional probability could be described for a single exposure as Pill ¼ fPinf ðdÞ. This resulting as a constant average dose, hence total number of illness for individual exposure is I ¼ NE4PinfðdÞ (22) 3.1. Acquired immunity from exposure
An individual may move from a disease susceptible compartment to full protection, partial protection and to total waning off of protection to become susceptible again. The acquired immunity for frequent exposure in a Susceptible (S), Full protection (P) and Partial protection (Q) (SPQ compartmental model) has the parameters shown in Table 1 . The deterministic first order differential equation for SPQ model can be described as follows;
where, all parameters are positive, thus S(0), P(0) and Q(0)>0. The Jacobian is represented as; 
For detðJ À XIÞ ¼ 0, the resulting characteristic equation is
Therefore, the eigenvalues of the characteristics equation are
and the corresponding eigenvectors are: ðag; lðl þ gÞ; alÞ; ð À g; ðg À aÞ; aÞ; ð1; 0; À 1Þ.
According to Swart et al. (2012) if R is assigned to be the average number of individual transition Susceptible compartment to Fully protection compartment before ultimately dying of natural cause, assuming no individual dies from illness from exposure, such a transition can be defined as R ¼ l Z ∞ 0 sðaÞFðaÞda, where s(a) is the probability of individual susceptibility at age 'a', and F(a) is the individual probability to survive until age 'a'. Therefore, the full and partial waning of immunity is given as;
The general solution using the eigenvalues and eigenvectors of equation are 0 @ sðaÞ pðaÞ qðaÞ 
The relevant solution for quantification of expected number of transition into the susceptible compartment after waning of immunity is given as;
Let the probability to survive until age 'a' be described by a survival function FðaÞ ¼ 1; 0 a A 0; a > A , where A is the life expectancy of the population under study, consequently, the total transition from S to P of an individual is
Henceforth, defining force of infection as l ¼ EPinfðdÞ where E is the total number of days of exposure to a pathogen, and whereas the factor t is obtained from binomial model of exposure as described in Messner et al. (2014) .
From Messner et al. (2014) , characterizing the impact of immunity by the inflation factor scaling the naïve model leads to the immunity model given as I ¼ tNE4P inf ðdÞ (36)
As dose d/∞ (Higher dose level), P inf ðdÞz1, Hence the immunity model in such a scenario is described as I ¼ tNE4 (37)
Modeling the hazard function of illness, let 0 t < L, where L is the entire period of infection for time t, therefore, the hazard function HðtÞ for probability of illness given infection from equation (12) can now be written as; 
Adoption of Gamma distribution for the unknown infection duration L to account for individual heterogeneity in resistance and persistence of host to colonization of infection leads to
Where u and hd are the shape and scale parameters of an underlying Gamma distribution for duration of infection describing the heterogeneity in response of subjects (Messner et al., 2014; Teunis et al. 1999 Teunis et al. , 2008 .
Therefore, the dose model is given as
Combined model with immunity and dose dependence
The dose-immunity model combines the effects of acquired immunity and dose-dependent conditional probability of illness (equation (37) and equation (43) 
Probabilistic simulation and data assimilation
Modeling the acquired temporary immune probability of illness requires multifaceted data input parameters to describe the various relations and probability distributions as shown in Table 2 . Data was gathered from various literature studies reporting on cases of norovirus based on quantitative risk assessment procedure. To improve on the results from limited data described in the available literature studies, simulations were performed based on the available data using Markov Chain Monte Carlo with hypercube sampling procedure for 100,000 iterations for each simulations. Computations were performed in Matrix Laboratory (MatLab) (www.mathworks.com/) and in R (www.rproject.org/) and using the mc2d package (Pouillot et al., 2015) with output designs carried out in Palisade Decision Suite (www.palisade.com/risk) and? @Risk built-in software for Excel version 7.5.2. Input parameters for the modeling are as shown in Table 2 .
Results on the modeling
The inclusion of temporary acquired immunity data for risk estimation gives a much lesser estimate of risk of illness compared to the naïve approach currently in use, as indicated (Fig. 1) . Comparatively, using the median risk of illness estimate, the dose model has an approximately 1 log less estimate than the naïve model. The immunity model recorded 2 logs less to the naïve model and a 1 log less to the dose model.
Moreover, by incorporating the disease immunity protection for the probability of illness given infection, the doseimmunity model had 3 logs, 2 logs and 1 log of magnitude less to the naïve model, dose model and immunity model respectively.
The impact measured by the inclusion of temporary acquired immunity shows a great difference in infection to illness estimation. Assuming a fixed dose of 1 norovirus particle, a constant daily exposure per annum and assigning a uniform distribution for the loss of full and partial immunity, the result shows a decline on incidence of illness from naïve, dose-model, immunity model and dose-immunity model, the immunity waning effect the total number that result in illness within the population, the illness number level saw a sharp decline when immunity model is used instead of naïve model, and hence by incorporating the effect of the dose dependent, the dose model and the dose-immunity model resulted in a further decline in prediction of illness numbers (Fig. 2) . [ Simmons, Gambhir, Leon, and Lopman (2013) 
Application to different illness scenarios with norovirus epidemiological data
The various transmission scenarios of norovirus included in this study are as described below;
Symptomatic Individual Infectious
Only symptomatic individuals are infectious. This comprises individuals in the population under the assumption that all exposed individuals are susceptible to norovirus infection and none is genetically resistant. It is worth noting that the naïve model dose do not relate to symptomatic individuals infectiousness. The earlier refers to estimation of risk without inclusion of temporary acquired immunity. Pre-symptomatic and Post-symptomatic infectiousness (Low) Pre-symptomatic persons are individuals exposed but yet to be symptomatic of the infection (Ozawa et., 2007; Simmons et al., 2013; Sukhrie et al., 2012; Sukhrie, Siebenga, Beersma, & Koopmans, 2010; Teunis et al., 2014) .
Pre-symptomatic and Post-symptomatic infectiousness (High)
In this scenario, individuals exposed and asymptomatic (Teunis et al., 2014) .
Innate Genetic Resistance
This is based on the assumption that part of the population is completely resistant to infection and disease, thus possessing the non-secretor phenotype and therefore playing no role in transmission process. However, such individuals do make contact with persons included in the empirical incidence estimate (Frenck et al., 2012) . This is also different from immunity model or dose-immunity models; the innate genetic resistance is the inclusion of individuals whose genetic make-up excludes them from infectiousness, yet forms part of the population.
Scenario E: Genogroup 2 Type 4 (GII.4)
The previous four (4) transmission scenarios assume all norovirus to be anti-genetically indistinguishable. In this scenario, it is assumed that only GII4 strains are infectious. The incidence of GII.4 is estimated based on values from (Huynen et al., 2013; Nordgren, Kindberg, Lindgren, Matussek, & Svensson, 2010; Vega et al., 2011) ; (Frenck et al., 2012) (Simmons et al., 2013) .
Scenario F: No Immune Boosting by Asymptomatic Infection
Persons do not travel from recovery of illness to direct asymptomatic individuals, the only pathway out of the recovery from illness is through waning of full and partial immunity to become susceptible again.
Data input for modeling scenarios above are based on epidemiological studies shown in Table 3 .
Results on the modeling
The Incidence of illness/infection models. The transmission dynamics in all scenarios had probability of infection/illness incidence for dose-immunity model within 3.32 Â 10 À8 e 7.11 Â 10 À8 , immunity model falls within 8.76 Â 10 À6 e 1.12 Â 10 À5 , dose model falls within 1.19 Â 10 À3 e 1.21 Â10 À3 and Naïve model falls within 1 Â10 À1 e 3.09 Â 10 À1 (Table 4) . A difference of 7 logs (median values) of magnitude was found between the dose-immunity and the naïve model for all epidemiological transmission dynamics. Five and 3 logs differences for dose-immunity as against the dose model and the immunity model, respectively. Hence, the probability of infection/illness decreases from the naïve, the dose model, the immunity model and the dose-immunity model. The individual infection/illness risk estimates for various immunity-incorporated models (dose-immunity, immunity) across the transmission scenarios gave a much lesser risk incidence as compared to the naïve and the dose-model approaches (Figs.  3e8) . Transmission dynamics. Across the different transmission dynamics scenarios with respect to their loss of partial and full temporary immunity protection levels (Table 4) , a comparison of models of the epidemiological scenarios using their median values did not show a difference in order of magnitude from transmission scenario to scenario with the exception of the immunity dose model which had 1 log less for pre-symptomatic and post-symptomatic low. Therefore, difference in the probability of infection/ illness is not sensitive to the epidemiological transmission scenarios, thus, norovirus transmissions dynamics does not influence the probability of infection/illness predictions (Table 5) . Furthermore, the findings observed no difference for all infection response models of the transmission dynamics for symptomatic infectiousness' and the 'no immune boosting after asymptomatic infectiousness' (Tables 4 and 5 ). This confirms the study by Teunis et al. (2014) which indicates that shedding of virus is similar for both symptomatic and asymptomatic infectiousness. However, it is worth noting that some differences were recorded studies for shedding of virus of infected subjects (Atmar, Opekum, & Gilger, 2008) . These differences are attributed to the genotype studied (Teunis et al., 2014) . Nevertheless, the difference in numbers shed could not have clinical significance, hence such indifference in risk estimate of illness as seen in this study is not unusual. Considering the findings under models without temporarily acquired immune inclusion (Table 4) , both the median values and mean values as well as their deviations were found to be the same for 'pre-symptomatic and post e symptomatic (high)' and 'symptomatic infectiousness' as well as recording similar estimates for 'innate genetic resistance and geno-group 2 Type 4' transmissions dynamics. This finding was not realized under any of the models or scenarios when acquired immunity is incorporated in the modeling process.
Conclusion
Applying the models to the norovirus data, resulted with the same trend of movement on the various dose-response models, and individual level of illness incidence reduction was much better measured by immunity incorporated models. The immunity incorporated models tend to predict a lower illness/infection incidence, while the non-immunity incorporated models do not. Again, the immunity dependent models (immunity and dose-immunity models) meet the more stringent WHO infection/illness threshold of 1:0 Â 10 À6 per person per exposure in all transmission scenarios.
The resulting magnitude of decrease in probability estimation of risk of illness is having a pronounced effect on the estimation of diseases as a result of incorporation of the temporary immune dose response, irrespective of the scenario of transmission of infected individuals, hence the results agree with Swart et al., 2012 and Swart, 2014 .
These modeling results throw more light on the overestimation of the probable infection/illness as a result of the use of naïve and dose models approach. It is important to note that the immunity model, which is a buildup of inclusion for immune system response in the first stage, is a better estimation in terms of predicting the reality of infection/illness of exposure than the naïve approach. The lower estimates for the immunity-incorporated models indicates the impacts of the temporary immune response to offer full protection and always results in lower estimates as compared to the naïve estimates (Tribble et al., 2010) . It is also important to note that the dynamics of the norovirus transfer from person to person does not influence the responses of the models, hence the prediction models superimpose on the type of the transmission of the virus.
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